Patients with epithelial ovarian cancer bearing BRCA1 or BRCA2 mutations have a better short-term survival (5 years) than noncarriers; however, this survival time was lost over time and after 5 years, BRCA1 carriers had a higher risk of dying than noncarriers, while a survival advantage longer persisted among BRCA2 patients [48]. This evidence concerns the gene BRCA2 and ovarian carcinoma.